These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18554312)

  • 1. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
    Laureillard D; Prak N; Fernandez M; Ngeth C; Moeung S; Riel V; Chhneang V; Song S; Quillet C; Piketty C
    HIV Med; 2008 Aug; 9(7):514-8. PubMed ID: 18554312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
    Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
    Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are adverse events of nevirapine and efavirenz related to plasma concentrations?
    Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
    Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
    Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Kiertiburanakul S; Wiboonchutikul S; Sukasem C; Chantratita W; Sungkanuparph S
    J Clin Virol; 2010 Apr; 47(4):330-4. PubMed ID: 20188624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tolerability of efavirenz after nevirapine-related adverse events.
    Clarke S; Harrington P; Barry M; Mulcahy F
    Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
    Berenguer J; Bellón JM; Miralles P; Alvarez E; Castillo I; Cosín J; López JC; Sánchez Conde M; Padilla B; Resino S
    Clin Infect Dis; 2008 Jan; 46(1):137-43. PubMed ID: 18171229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
    Mouhari-Touré A; Saka B; Kombat K; Tchangaï-Walla K; Pitche P
    Bull Soc Pathol Exot; 2008 Dec; 101(5):404-6. PubMed ID: 19192611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
    Mulenga V; Cook A; Walker AS; Kabamba D; Chijoka C; Ferrier A; Kalengo C; Kityo C; Kankasa C; Burger D; Thomason M; Chintu C; Gibb DM
    Clin Infect Dis; 2010 Nov; 51(9):1081-9. PubMed ID: 20868279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
    Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
    J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.